Latest news with #MicafunginforInjection
Business Standard
12 hours ago
- Business
- Business Standard
Glenmark Pharma's US arm to launch Micafungin injection in the US market
Glenmark Pharmaceuticals announced that its U.S.-based subsidiary, Glenmark Pharmaceuticals Inc., USA, will launch Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial), in the U.S. market this September. The product is bioequivalent and therapeutically equivalent to the reference listed drug Mycamine for Injection, 50 mg/vial and 100 mg/vial, originally developed by Astellas Pharma US, Inc. The company will begin distribution in September 2025. According to IQVIA sales data for the 12-month period ending June 2025, the U.S. market for Mycamine for Injection generated annual sales of approximately $60.7 million. Micafungin is an echinocandin antifungal used primarily in the treatment of candidemia, esophageal candidiasis, and for prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Marc Kikuchi, president & business head, North America said, We are excited to announce the launch of Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial), growing our portfolio of products within the institutional channel, while also strengthening our commitment to bring quality and affordable alternatives to market for patients in need. Glenmarks Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial) is only approved for the indication listed in Glenmarks approved label. All brand names and trademarks are the property of their respective owners. Market includes brand and all available therapeutic equivalents. Note: IQVIA data obtained by Glenmark is only available for all approved RLD indications. Glenmarks product is only approved for the indications listed in Glenmarks approved label and is not marketed for all RLD indications. IQVIA National Sales Perspectives: Retail & Non-Retail, June 2025. Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company's consolidated net profit jumped 49.9% to Rs 215.48 crore on 7.4% rise in revenue from operations to Rs 1505.62 crore in Q1 FY26 over Q1 FY25. The scrip declined 1.38% to Rs 1,947.10 on the BSE.
News18
13 hours ago
- Health
- News18
Glenmark to launch injection to treat fungal infections in US
Agency: Last Updated: New Delhi, Aug 19 (PTI) Glenmark Pharmaceuticals Inc., USA on Tuesday said it will launch Micafungin for injection, used to treat fungal infections, in the US market. Micafungin for injection will be launched in strengths of 50 mg/vial and 100 mg/vial in a single dose, the company said in a statement. The company will begin distribution in September 2025, it added. The launch of Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (single-dose vial) will grow the company's portfolio of products within the institutional channel, while also strengthening its commitment to bring quality and affordable alternatives to market for patients in need, Glenmark President & Business Head, North America Marc Kikuchi said. Glenmark's Micafungin for Injection 50 mg/vial and 100 mg/vial in single dose is bioequivalent and therapeutically equivalent to the reference listed drug, Mycamine for injection, 50 mg/vial and 100 mg/vial, of Astellas Pharma US, Inc. Citing IQVIA sales data for the 12-month period ended June 2025, the company said the Mycamine ® for Injection, 50 mg/vial and 100 mg/vial, market achieved annual sales of approximately USD 60.7 million. PTI RKL SHW view comments First Published: August 19, 2025, 13:15 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy. Loading comments...
